This is exactly correct HGilS. Let me explain why I am potentially very excited about this launch. The interesting fact that Elite even had API prior to approval should be a big tip off. Then the API manufacture had to answer questions about their DMF. This all points to Elite qualifying a new API supplier to a severally constrained API market. As JamesF1 stated prior the only other generic that seems to be in stock steadily is Sun Pharma and this makes sense as they own Chattem Chemical, who has the API approved and I am guessing they are using their own source. All the others and this is my opinion are using the same API source as the brand and who do you think has priority in that arrangement regardless of quota. Now fast forward to the current DEA quota process. If a company does not use their quota, I think this is quarterly, they have to give it back to the pool. Now if Elite has an API supplier that does not have supply issues and quota is being given back, who do you think gets the quota, Elite! This whole scenario plays into my belief that Elite will get 10-20% of the market quickly and to be honest that is all we need, 1 year of those sales. With that massive amount of cash, Nasrat implements a 20-30% share buyback, using the $300-400M extra profits, pushing us into Nasdaq price range, we uplist and the company gets bought out. This is my strong belief of what we are about to see play out in 2025. He may also be holding off announcing the new product BE and filings until next year for added fuel to catch everyone off guard. Keep in mind he does not have to announce anything pertaining to the new drugs. Anyway, just fun to speculate at this point. Also, someone asked me a question with regards to international DEA quota for the Dexcel launch, I am still researching that as I've never experienced a launch in Israel and how it pertains to controlled drugs. Cheers and happy holidays everyone!
AI
Market Data 
Markets 
